middle.news
Why Did Opthea Halt Sozinibercept After Phase 3 Trial Failures?
8:22pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
Why Did Opthea Halt Sozinibercept After Phase 3 Trial Failures?
8:22pm on Friday 29th of August, 2025 AEST
Key Points
Phase 3 COAST and ShORe trials failed to meet primary endpoints
Sozinibercept program for wet AMD terminated
Development Funding Agreement settled with $20M cash and equity issuance
Workforce and board significantly reduced
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE